4.7 Article

Impact of Glucose Loading on Variations in CD4+ and CD8+ T Cells in Japanese Participants with or without Type 2 Diabetes

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2018.00081

Keywords

proportion of CD4(+) and CD8(+) T cells; oral glucose tolerance test; glucose loading; glucose metabolism; lymphocytes

Funding

  1. Ministry of Education, Culture, Sports, Science, and Technology, Japan

Ask authors/readers for more resources

Objective: The aim of this study was to examine the fluctuations in CD4(+) T cells, CD8(+) T cells, and natural CD4(+)CD25(+)FoxP3(+) T-regulatory (Treg) cells following an oral glucose tolerance test (OGTT) in participants with and those without type 2 diabetes (T2DM). Methods: 19 Japanese participants with T2DM (DM group) and 21 participants without diabetes (non-DM group) were recruited and underwent a 75-g OGTT. The cell numbers of leukocytes, lymphocytes, and the T cell compartment, such as CD4(+), CD8(+), and Treg, were calculated for blood samples obtained after an overnight 12 h fast and during a 75-g OGTT at 60 and 120 min. Results: Before glucose loading, no differences in the cell numbers of leukocytes, lymphocytes, CD4(+), CD8(+), and Treg were observed between the DM group and the non-DM group. The proportion of CD8(+) was significantly reduced, whereas the proportion of CD4(+) was significantly increased, after 120 min of glucose loading in both groups. The proportion of Treg was not affected. Furthermore, a significant positive correlation was observed between the AUC(0-120 min) of CD8(+) and the change in the free fatty acid level following the OGTT (rho = 0.39, P < 0.05), but not that of glucose or insulin. Conclusion: The proportion of CD4(+) T cells was increased and that of CD8(+) T cells was reduced after glucose loading in both subjects with and without diabetes. These findings suggest that glucose loading dynamically affects the balance of the circulating T lymphocyte subset, regardless of glucose tolerance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi

Summary: This study found that SGLT2 inhibitors have good efficacy and safety in patients with type 1 diabetes, significantly decreasing glycated hemoglobin and body weight, reducing insulin dose, improving day-to-day glucose variability, and increasing the time spent in the target glucose range.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment

Aika Miya, Akinobu Nakamura, Takahisa Handa, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi

Summary: The study identified a CV of 40 as the threshold that distinguishes unstable glucose variability and hypoglycemia from stable GV in Japanese outpatients with type 2 diabetes. Impaired insulin secretion might affect the stability of glucose variability.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi

Summary: The study found that compared to switching from a dipeptidyl peptidase-4 inhibitor to a sodium-glucose cotransporter 2 inhibitor, combination therapy with both types of inhibitors may be a better option for improving daily glucose variability in patients with impaired endogenous insulin secretion.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

Kyu Yong Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Kohei Yamamoto, Hiroshi Nomoto, Hiraku Kameda, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi

Summary: Dapagliflozin may be more beneficial than pioglitazone for patients with NAFLD, and improvements in FLI are closely related to glycemic control.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

Arina Miyoshi, Hiraku Kameda, So Nagai, Akinobu Nakamura, Aika Miya, Takahiro Takase, Tatsuya Atsumi, Hideaki Miyoshi

Summary: This study included 48 patients divided into four groups, and the results showed that switching to Dmab from BP or SERM is beneficial in preventing osteoporosis progression in postmenopausal patients with type 2 diabetes mellitus.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi

Summary: Combining sodium-glucose cotransporter 2 inhibitor with dipeptidyl peptidase-4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Endocrinology & Metabolism

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study

Takahisa Handa, Akinobu Nakamura, Aika Miya, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Narihito Yoshioka, Hideaki Miyoshi, Tatsuya Atsumi

Summary: Among elderly patients with type 2 diabetes, the coefficient of variation (CV) is the most appropriate index that best reflects TBR >= 1% among the glycemic variability (GV) indices examined. Clinical characteristics including HbA1c and C-peptide index were not independent markers for TBR >= 1% in the multivariate logistic regression analysis, while all three GV indices showed significant associations with TBR >= 1%.

DIABETOLOGY & METABOLIC SYNDROME (2021)

Article Multidisciplinary Sciences

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring

Aika Miya, Akinobu Nakamura, Takahisa Handa, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Yoichi M. Ito, Hideaki Miyoshi, Tatsuya Atsumi

Summary: In patients with type 2 diabetes, there is a negative log-linear relationship between fasting C-peptide levels and glycemic variability, with low C-peptide levels being a predictor of high glycemic variability. Endogenous insulin secretion contributes to glycemic variability depending on the extent of insulin secretion impairment. Fasting C-peptide may serve as a useful indicator of glycemic variability instability in type 2 diabetes.

SCIENTIFIC REPORTS (2021)

Article Endocrinology & Metabolism

Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis

Yuka Takahashi, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Hiroki Nishimura, Hirokazu Kimura, Masaru Suzuki, Satoshi Konno, Ai Shimizu, Yoshihiro Matsuno, Michinari Okamoto, Hiroaki Motegi, Naoko Iwata, Haruki Fujisawa, Atsushi Suzuki, Yoshihisa Sugimura, Hideaki Miyoshi, Tatsuya Atsumi

Summary: The purpose of this study was to explore the clinical significance of anti-rabphilin-3A antibody for the differential diagnosis of lymphocytic panhypophysitis. A case analysis of a 58-year-old Japanese man revealed lymphocytic panhypophysitis comorbid with sarcoidosis. Biopsies of the hilar lymph nodes and anterior pituitary confirmed the diagnosis, and the detection of anti-rabphilin-3A antibody played an important role in the differential diagnosis.

PITUITARY (2022)

Article Endocrinology & Metabolism

False Hypercortisolemia Due to Abnormal Albumin-Cortisol Binding in a Patient with Familial Dysalbuminemic Hyperthyroxinemia

Koki Chiba, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Shigeki Jin, Kotaro Matoba, Hideaki Miyoshi, Tatsuya Atsumi

THYROID (2022)

Article Endocrinology & Metabolism

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi

Summary: This study investigated the effect of switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) on glycemic variability in patients with type 2 diabetes. The results showed that switching to IDegLira significantly improved glycemic variability and other indices. IDegLira might be beneficial for patients being treated with low-dose basal insulin.

JOURNAL OF DIABETES RESEARCH (2022)

Article Geriatrics & Gerontology

The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8): A cross-sectional study of elderly patients with diabetes

Aika Miya, Akinobu Nakamura, Isao Yokota, Kyu Yong Cho, Hiraku Kameda, Hiroshi Nomoto, Takahiro Takase, Kazuno Omori, Mayuko Ono, So Nagai, Shinji Taneda, Hideaki Miyoshi, Tatsuya Atsumi

Summary: The achievement of individualized target HbA1c based on the DASC-8 assessment in elderly patients with diabetes is low, and certain patient characteristics may act as barriers to reaching the target HbA1c.

GERIATRICS & GERONTOLOGY INTERNATIONAL (2022)

Letter Geriatrics & Gerontology

Urethral injury related to peri-urethral abscess as a complication of self-catheterization in an older patient with type 2 diabetes

Yuri Ofuji, Hiroshi Nomoto, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi

GERIATRICS & GERONTOLOGY INTERNATIONAL (2022)

Article Endocrinology & Metabolism

Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study

Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yoichi M. Ito, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi

Summary: This study evaluated the contribution of body fat mass and serum adiponectin concentration to glucose variability stability in people with impaired and preserved endogenous insulin secretion in type 2 diabetes. The results showed that in those with preserved endogenous insulin secretion, glucose variability was not related to abdominal fat area. However, in those with impaired endogenous insulin secretion, glucose variability was significantly related to small abdominal visceral fat area and small subcutaneous fat area. There was no significant relationship between serum adiponectin concentration and continuous glucose monitoring-related variables.

DIABETES OBESITY & METABOLISM (2023)

Article Pharmacology & Pharmacy

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis

Hiroshi Nomoto, Yuka Takahashi, Yoshinari Takano, Hiroki Yokoyama, Kazuhisa Tsuchida, So Nagai, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Tatsuya Atsumi

Summary: This subanalysis suggests that switching from conventional glucagon-like peptide-1 receptor agonists to once-weekly semaglutide may be beneficial for individuals with NAFLD complicated with T2DM. The improvement in fatty liver index (FLI) was greater in those who switched from dulaglutide and significantly correlated with older age and lower baseline FLI.

PHARMACEUTICS (2023)

No Data Available